Eli Lilly seeks to quell drug price anger with cheaper insulin

(Reuters) – Drugmaker Eli Lilly announced plans on Monday to sell a half-price version of its popular insulin injection Humalog, as it fends off criticism about rising drug prices in the United States.

FILE PHOTO: The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim near Strasbourg, France, February 1, 2018. REUTERS/Vincent Kessler

Major drugmakers including Lilly, a leading producer of insulin, have come under fire from patients and lawmakers over the rising cost of the life-saving medication used to treat diabetes.

U.S. senators last week grilled executives from major drug companies, calling their pricing practices “morally repugnant”.

Lilly’s rebranded product will be called Insulin Lispro, while Humalog, which makes $3 billion in annual sales, will remain available for those wishing to access it through existing insurance plans.

The cost of insulin for treating type 1 diabetes in the United States has nearly doubled over a five-year period, leading some patients to put their own health at risk by rationing the medication.

The list price for Lilly’s authorized generic, to be sold only in the United States, will be $137.35 per vial.

“Today’s announcement indicates that Lilly has calculated that the resultant impact of the introduction is at worst, economically neutral with the potential for material political gain,” Citi analyst Andrew Baum said.

Two senators last month launched an investigation into rising insulin prices, writing to Lilly and other leading manufacturers, asking them why the cost of the nearly 100-year-old medication had rapidly risen.

The price of Lilly’s Humalog rose from $35 to $234 per dose between 2001 and 2015, a 585 percent increase, the senators, Republican Chuck Grassley and Democrat Ron Wyden, had said.

Grassley on Monday called Lilly’s announcement “good news” in a Twitter post but added it was “only 1 piece of puzzle” and more needed to be done. Wyden said via email that Lilly’s move would be a part of the Senate Finance Committee’s investigation.

Meanwhile, Novo Nordisk and Sanofi SA, two other major insulin producers, told Reuters they were already taking steps to make insulin more affordable.

Novo said it was offering insulin at $25 per vial at many national pharmacy chains and had a program to help uninsured patients. Its insulin has a list price of $137.70.

Sanofi said its insulin products were provided to uninsured or commercially insured patients for half their list price under a program launched last year.

Lilly has in the past called insulin a highly-rebated product. Drugmakers often argue they have to keep prices high because of rebates or after market-discounts they must pay to pharmacy benefit managers and health insurers to get products on their lists of covered drugs.

The U.S. government in January proposed a rule to end the industry-wide system of rebates, a change that Lilly says it would welcome.

Reporting by Manas Mishra in Bengaluru; Editing by Sai Sachin Ravikumar

Source

more recommended stories

  • Senator Gillibrand wants insurance to pay for fertility treatments

    WASHINGTON (Reuters) – U.S. Democratic presidential.

  • Hundreds rally at U.S. Supreme Court, calling state abortion bans as step backward

    WASHINGTON (Reuters) – Abortion-rights campaigners, including.

  • French court says doctors must resume life support for paralyzed patient

    STRASBOURG, France (Reuters) – A French.

  • Missouri follows Alabama by passing restrictive abortion bill

    (Reuters) – Missouri lawmakers passed a.

  • Too much screen time tied to school problems even in little kids

    (Reuters Health) – Kindergarteners who get.

  • Smokers have higher risk for multiple strokes

    (Reuters Health) – Smokers who have.

  • Missouri assembly passes restrictive abortion bill, days after Alabama

    (Reuters) – The lower house of.

  • Missouri Senate passes bill to ban abortions after eight weeks

    (Reuters) – Missouri’s Senate passed a.

  • Alabama governor signs strictest U.S. abortion ban into law

    (Reuters) – Alabama’s governor signed a.

  • Alabama Senate bans nearly all abortions, including rape cases

    (Reuters) – Alabama’s state Senate passed.

  • Israel regulator warns of medical cannabis bubble, eyes Australia pact

    JERUSALEM (Reuters) – Medical cannabis could.

  • U.S. measles outbreak grows with 75 new cases, mostly in New York

    (Reuters) – U.S. health authorities recorded.

  • Teva Pharm CFO says company did not conspire to fix prices

    FILE PHOTO: The logo of Teva.

  • U.S. states accuse Teva, other drugmakers, of price-fixing: lawsuit

    WASHINGTON (Reuters) – U.S. states filed.

  • Exclusive: Philip Morris suspends social media campaign after Reuters exposes young ‘influencers’

    (Reuters) – Cigarette maker Philip Morris.

  • Hong Kong reports African swine fever case

    HONG KONG (Reuters) – Hong Kong.

  • Alabama Senate delays vote on strict anti-abortion bill

    (Reuters) – Alabama’s state Senate on.

  • Denver votes to become first U.S. city to decriminalize ‘magic mushrooms’

    Psilocybin or “magic mushrooms” are seen.

  • AstraZeneca-Daiichi Sankyo breast cancer drug shows promise

    The company logo for pharmaceutical company.

  • Denver to vote on decriminalizing ‘magic mushrooms’

    FILE PHOTO: Boxes containing magic mushrooms.

  • Trans teens face higher sexual assault risk when schools restrict bathrooms

    (Reuters Health) – Transgender adolescents may.

  • U.S. doctors use medical records to fight measles outbreak

    CHICAGO (Reuters) – U.S. doctors are.

  • UK’s Vectura wins patent infringement case against GlaxoSmithKline in U.S

    (Reuters) – British drugmaker Vectura Group.

  • Tyson Foods recalls almost 12 million pounds of chicken strips over contamination fears

    (Reuters) – Tyson Foods Inc significantly.

  • Monstrous rumors stoke hostility to Pakistan’s anti-polio drive

    PESHAWAR, Pakistan (Reuters) – His bearded.

  • U.S. health agency finalizes conscience and religious freedom rule

    WASHINGTON (Reuters) – The U.S. Department.

  • Medication use drops when local drugstores close

    (Reuters Health) – People are less.

  • EPA says popular weed killer glyphosate is not a carcinogen

    CHICAGO (Reuters) – The U.S. Environmental.

  • Novartis’s Sandoz strikes deal for biosimilar of Herceptin

    FILE PHOTO: Swiss drugmaker Novartis’ logo.

  • U.S. measles outbreak triggers quarantine at two Los Angeles universities

    LOS ANGELES (Reuters) – A nationwide.

  • U.S. measles outbreak raises questions about immunity in adults

    (Reuters) – Adults in the United.

  • FDA approves expanded label for Regeneron/Sanofi’s cholesterol drug

    (Reuters) – The U.S. Food and.